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Box 1: What you need to know 
• Positive antibodies demonstrate evidence of prior exposure to SARS-CoV-2 virus 
• Antibody testing should be undertaken at least 2 weeks after symptom onset 
• The sensitivity and specificity of antibody tests varies over time and results should be 
interpreted in context of the clinical history 
• Antibody testing could have a useful role in covid-19 diagnosis in patients with late 
presentation, prolonged symptoms or negative RT-PCR tests 





The covid-19 pandemic represents a significant challenge to clinicians, to healthcare systems and to 
public health globally. Diagnosis can be challenging as symptoms can vary significantly, and false 
negative RT-PCR tests occur,1 particularly when swabs are done more than 5 days after symptom 
onset, when sensitivity of RT-PCR tests starts to decrease.2 A significant proportion of infections may 
also be asymptomatic,3 and many in the UK who have had COVID-19 symptoms isolated at home 
without ever being tested. The emotional strain of the current pandemic is significant, leading to 
fear and a desire for reassurance and certainty. Consequently there has been substantial interest in 
antibody testing, both to measure how far the infection has spread and to identify individuals who 
have antibodies, as lockdowns are gradually lifted.4 Despite a rapidly increasing number of research 
papers, there is a lack of clarity about how these tests fit into clinical pathways, and how to interpret 
results. The UK government has announced that antibody testing should be offered to anyone 
having their blood taken who wants to know whether they have been infected with covid-19, even if 
there is ‘not a specific clinical indication’,5 yet currently there is no clear guidance for clinicians on 
how to interpret these results to make optimal decisions for individual patients. The UK are soon to 
introduce the UK-Rapid Test Consortium “AbC-19TM Rapid Test” and promise that it will be widely 
available to the public. (https://www.abingdonhealth.com/uk-covid-19-rapid-antibody-tests-
approved-for-professional-use/)  
 
Who might benefit from antibody testing? 
 
There are four main possible reasons for covid-19 antibody testing; 
1) For diagnosis of individuals with current symptoms suggestive of covid-19,  when antigen 
testing has failed to detect SARS-CoV-2, especially those who present  two weeks or more 
after symptom onset (when antibody testing becomes more reliable).  
2) For individuals who are currently asymptomatic, to assess if they have had a previous SARS-
CoV-2 infection. This may include people at higher risk of severe disease eg BAME groups or 
those with occupational risk of infection eg healthcare workers, in order to provide 
reassurance, or to inform personal decisions about returning to work. 
3) To monitor the quality and longevity of the immune response in patients with previously 
confirmed covid-19 disease.  This enables our basic understanding of the immune response 
to covid-19, but this has clinical application by informing vaccination responses. If treatment 
with convalescent plasma is found effective in treatment COVID-19, antibody tests will also 
have a role in identifying suitable donors. 
4) For seroprevalence surveys for research and public health monitoring. 
In this article we will not discuss the latter two indications, but will focus on the benefits of antibody 
testing for individuals with and without symptoms suggestive of current or past covid-19 infection.   
 
Accuracy of antibody tests 
There are three main types of antibody produced in response to infection; IgA, IgG and IgM. IgM 
rises soonest and typically declines after infection, IgG and IgA persist and usually reflect longer term 
immune response. Antibody tests include a variation of the above antibodies, either as separate or 
combined antibody measurement.  Antibody tests can be done in laboratory settings using enzyme-
linked immunosorbent assays (ELISA) or chemiluminescence immunoassays (CLIA) usually using 
venous blood samples. Point of care tests using disposable devices called lateral flow assays (LFAs) 
which use finger prick blood are also available. The main tests currently used in the NHS in the UK 
are the Abbott SARS-CoV-2 assay which detects IgG and the Roche Elecsys assay which detects both 
IgM and IgG. Both are CLIA assays which require venous blood. The accuracy of antibody tests is 
measured by comparing the test results to a ‘gold standard’, usually viral RNA detection by PCR 
testing at the time of symptoms. A limitation of this approach is the sensitivity in PCR testing. We do 
not yet have studies that measure outcomes such as rates of future Infection. Accuracy is therefore 
a measure of how well the tests detect previous covid-19 infections, not a direct measure of 
immunity to future infections.  
 
A recent Cochrane review of covid-19 antibody testing included 57 publications on 54 cohort studies 
with 15,976 samples of which 8,526 were from cases of confirmed SARS-CoV-2 infection.6 Measures 
of diagnostic accuracy varied depending on the timing of the tests (see table 1). The maximum 
sensitivity for combined IgG or IgM tests was 96%  at days 22-35 post symptom onset. For IgG alone 
the maximum sensitivity was 88.2% at days 15-21 post symptom onset. Summary specificities were 
provided in 35 out of 54 studies and exceeded 98% for all types of antibody test. The authors warn 
that these estimates of accuracy must be interpreted with caution, as 89% of studies in the review 
were judged to be at high risk of bias. The potential consequence is that many of the tests are likely 
to be less sensitive than reported, meaning increased likelihood of false negatives. The majority only 
included patients who were diagnosed based on a positive RT-PCR test, which means that patients 
who have signs, symptoms and exposure to COVID-19 but negative PCR (who are defined in the 
China CDC and WHO case definitions as “probably COVID”) are excluded.  This is important as false 
negative rates of PCR have been estimated between 2% and 29%7. Most studies recruited 
hospitalised patients often with severe symptoms who are likely to have a greater antibody 
response than those in community settings. None directly measured test accuracy in asymptomatic 
patients, who have been shown to have lower levels of IgG and greater reductions in antibody levels 
in the early convalescent phase.8 Nearly all studies sampled covid-19 cases and non-cases 
separately; this methodology leads to bias and tends to over-estimate measures of accuracy.9  
There was a lack of data on accuracy of tests beyond 35 days. The optimum time for covid-19 
antibody testing based on current research appears to be 2-5 weeks post symptom onset. Tests 
performed after 5 weeks should be interpreted with caution, as there is some evidence to suggest 
antibody levels may wane,10 which would be expected to decrease sensitivity of antibody tests and 
increase false negatives. 
 
Interpreting antibody tests 
Interpretation of test results depends not only on the accuracy of the test itself but also the pre-test 
probability of infection. This will vary significantly depending on the indication for testing; when 
screening asymptomatic individuals this will be relatively low, for those with suggestive symptoms it 
is likely to be much higher. We will illustrate this with two clinical cases. 
Case 1 
Anthony is 53 with a background of type 2 diabetes and a raised BMI. He works as a security guard in 
a shopping centre in Norwich. His wife is worried about his risk of exposure to covid-19 at work, and 
phones the GP surgery requesting an antibody test. He has not had any suggestive symptoms and 
has no known exposure, having been off work since the start of the pandemic.  
Anthony’s pre-test probability can be estimated based on the population covid-19 antibody 
seroprevalence in his area; in the East of England this is estimated to be around 10%.11 As he has had 
no symptoms or known exposure his probability of asymptomatic seroconversion is likely to be 
lower; for illustrative purposes we will estimate his pre-test probability at 5%.  
We do not have any data on the accuracy of antibody assays in asymptomatic people to base our 
estimates on.  We will start by using the average sensitivity of 91.4% and average specificity of 98.7% 
from the Cochrane review and consider what would change, if in all likelihood, the test had lower 
sensitivity. Figure 1a illustrates the outcomes of testing based on 1000 people like Anthony, with a 
pre-test probability of 5%. We would expect that 942 people would test negative, of whom 4 people 
(0.4%) would actually have had had covid-19 (false negatives). Considering that the test may well 
have lower sensitivity, particularly if the peak incidence and therefore likely time of infection is >35 
days ago, this would proportionally increase the false negative rate. If the test made five times as 
many false negatives (sensitivity of 57%) then this would rise to 20 false negatives (2.1%) - still 
relatively low numbers due to the low prevalence. A negative test result would therefore mean 
Anthony is unlikely to have had covid-19 infection. However, of the 58 people who would test 
positive, 12 people (21%) would be falsely positive. This is important because a false positive could 
potentially influence Anthony’s behaviour and adherence to infection control measures. This could 
be particularly risky as Anthony has an occupational risk of exposure and co-morbidities making him 
at higher risk of complications from covid-19. The GP should therefore explain that the test result 
cannot be used to indicate immunity, and that regardless of the results of testing Anthony should 
take precautions to avoid exposure to SARS-CoV-2. The test result in this case is therefore unlikely to 
change clinical management of the patient, and has the potential to cause harm through false 
reassurance.   
 
Case 2  
Sarah is 32 and has been unwell for 4 weeks with intermittent shortness of breath, myalgia, atypical 
chest pains, fatigue and anosmia. She never received a covid-19 swab test, as she did not have 
typical cough or fever symptoms. Her GP requests blood tests including covid-19 antibodies. 
Sarah has prolonged symptoms which are in keeping with a possible diagnosis of coronavirus, 
although she has not had suffered the cardinal features of cough or fever. To try and clarify the 
underlying cause of Sarah’s symptoms before embarking on further investigations, her GP requests 
blood tests including covid-19 antibodies. Her pre-test probability will be higher than Anthony, and 
will also depend on where she lives and whether she is known to have been exposed to the virus – 
for illustrative purposes we will estimate her pre-test probability of 50%.  We will use the estimates 
of sensitivity and specificity for the test from the Cochrane review.6 
Figure 1b shows the outcomes of testing based on 1000 people with a pre-test probability of 50%; 
537 people would be expected to test negative, of whom 43 (8%) would have actually had covid-19 
(false negatives). If the sensitivity was not as high as in the Cochrane review (which is likely because 
of the limitations of the primary studies that they mention) then number of false negatives would 
increase. This means a negative test in a patient like Sarah makes covid-19 less likely, but does not 
rule it out; Sarah might have had covid-19 but never developed an antibody response, her antibody 
levels could have dropped in the 4 weeks since symptom onset, or the test could have been unable 
to detect the antibodies which were present. However, the negative result would alert the clinician 
to consider other possible causes for Sarah’s symptoms, which could help prevent missed or delayed 
diagnosis of other diseases in patients with symptoms assumed to be covid-19 related.  
A positive test in this context would be much more compelling; of 1000 people tested, 464 people 
would test positive and only 7 (2%) would not have covid-19 (false positives). A positive test result in 
the context of suggestive symptoms therefore makes covid-19 infection highly probable. Antibody 
testing is therefore likely to be helpful in guiding clinical management of symptomatic patients like 
Sarah.  
In summary, antibody tests have a high specificity, but sensitivity is variable and depends on time 
since symptom onset. Negative results should therefore be interpreted with caution in the context 
of typical symptoms. High specificity means false positives are rare (<2% of people who have not had 
covid-19 will have a false positive test). However in low prevalence settings true positives are also 
rare, which means the predictive value of a positive test will be lower in individuals with a low 
background risk of infection. A positive result must therefore also be interpreted with caution in 
patients with a low pre-test probability, such as those with no history of suggestive symptoms or risk 
factors for exposure to SARS-CoV-2, as false positives could lead to false reassurance with potential 
for patient harms. This interactive calculator 
(https://www.bmj.com/content/369/bmj.m1808/article-info) allows clinicians to explore the impact 
of changing the pre-test probability, sensitivity and specificity on test outcomes. Residual 
uncertainty after diagnostic testing is normal, and the same principles apply to most screening and 
diagnostic tests. Covid-19 offers an opportunity to improve clinician and patient understanding and 
communication of risk and uncertainty in diagnostic testing. This raises a wider debate around 
testing and test evaluation for many diseases where the accuracy of tests has not been subject to 
this degree of scrutiny. 
 
SARS-CoV-2 immunity 
Antibodies are an essential component of the adaptive immune response providing specificity and 
memory against future infection. This is achieved through a number of mechanisms including 
neutralization by binding pathogens, activation of complement to destroy cells by lysis, presentation 
or opsonisation to immune cells to facilitate phagocytosis, degranulation and antibody dependent 
cell-mediated cytotoxicity.   
However, for many viruses and intracellular infections such as tuberculosis, T cell immunity is 
predominant. There is an increasing literature on the role of T cells following SARS-CoV-2 infection.12 
T cell memory has now been demonstrated in laboratory tests, and cross reactivity of T cell 
responses to other coronavirus infections potentially explains some of the variation in clinical 
severity of infection.13 As for most intracellular infections, it is likely that a combination of B and T 
cell immunity is required for clearing covid-19 infection and generating protective memory. 
Although we can test for the presence of antibodies, the extent to which SARS-CoV-2 antibodies 
provide future immunity and protection from repeat infection is not yet known. There is 
experimental evidence of neutralization with certain SARS-CoV-2 antibodies and inferred clinical 
evidence from very few reports of repeat infection and successful use of convalescent plasma 
therapy.14 15 However, longitudinal studies are now reporting and showing that antibody levels are 
waning.10 What we do not know is whether protective immunity will be maintained with a lower 
antibody titre. 
To know whether our current antibody tests are indicative of protective immunity, ideally we would 
need disease prevalence studies in individuals with known antibody status, however knowing 
whether these antibodies are neutralizing in a laboratory should give us some indication before large 
population studies can be completed.   
Lastly, antibodies have the ability to provide long term immunity but non neutralizing antibodies can 
also be produced and a phenomenon known as antibody enhancement can occur where antibodies 
facilitate a secondary infection that can be more severe than the primary infection.17 This has been 
reported with other corona viruses but not to date with SARS-CoV-2.   
 
Pitfalls of antibody testing  
Testing policies that are population based and without a specific clinical indication, essentially 
amount to screening. This risks potential harm if the consequences of testing are not carefully 
considered. If testing is based on patient request, rather than clinically driven, we anticipate that 
there will be higher rates of testing in more affluent populations, who are at lower risk of covid-19, 
in keeping with the inverse care law.18 This also limits the usefulness of data for estimates of 
seroprevalence, as a self-selecting population will not be representative. Concerns about the 
implications of the rapid rollout of antibody testing have been raised19 and the CMO in Scotland has 
advised against ‘on-demand’ testing.20  
The Royal College of Pathologists has produced a covid-19 testing strategy, underpinned by seven 
principles, one of which is that testing must be carried out for a purpose.21 It is arguable that doctors 
commonly use tests for the purposes of ‘reassurance’, 22 and this is therefore a justifiable rationale 
for testing. However two systematic reviews of randomised controlled trials found no evidence of 
effect of diagnostic tests on illness worry, non-specific anxiety or symptom persistence;23 24 we do 
not know the effect of covid-19 testing on patient anxiety. There have been suggestions that the 
purpose of antibody testing should be to guide reopening of workplaces,25 however until more is 
known about the relationship between antibodies and protective immunity results should not 
influence public health advice to individuals or workplaces. Even if future evidence demonstrates 
that antibodies do confer sufficient and lasting immunity, the concept of ‘immunity passports’ raises 
ethical issues, threatening freedom and fairness and potentially risking public health by incentivising 
people to wilfully seek out infection and antibody testing or encouraging a potential antibody testing 
black market.26  
Public and political demand for testing should be balanced against the significant workload 
generated for laboratories doing the tests and GPs discussing implications before testing and results 
with patients. However if tests are not available through an NHS route, individuals may seek to 
access tests through private means where tests may not be as rigorously quality assured and 
individuals are less able to access the clinical interpretation of the result within the context of an 
individual’s situation.  
 
Conclusions 
Antibody testing within rigorously designed and conducted seroprevalence studies is important for 
research and to guide public health interventions.27 However clinicians should consider the risks and 
benefits of testing for individuals, and should carefully share information about the limitations of 
testing with patients (box 5). High quality evidence on test accuracy is currently lacking, and further 
research is needed to address areas of uncertainty (box 6). For most asymptomatic individuals 
knowing their antibody status it is unlikely to change clinical management. A drive to increase 
volumes of tests performed without considering the clinical value of testing could be an expensive 
distraction from key public health interventions. Yet carefully considered testing, in patients with 
late presentation of the illness, prolonged or atypical symptoms could help reduce uncertainty, 
guide ongoing management and improve understanding of the late sequelae of covid-19.  
 
Table 1: Sensitivity and specificity by time since symptom onset6 
 Sensitivity Specificity 
 Days 1-7 Days 8-14 Days 15-21 Days 22-35 Days >35 All time 
points 

















































*The main tests currently used in the NHS in the UK are the Abbott SARS-CoV-2 assay which detects IgG and the Roche 
Elecsys assay which detects both IgM and IgG. 
 
Box 2: Definitions 
 
Sensitivity (or true positive rate): proportion of people who have had covid-19 who are correctly 
identified by a positive antibody test 
Specificity (or true negative rate): proportion of people who have not had covid-19 who are 
correctly identified by a negative antibody test 
True positives: people who have had covid-19 who have a positive test result 
False positives: people who have not had covid-19 who have a positive test result 
True negatives: people who have not had covid-19 who have a negative test result 
False negatives: people who have had covid-19 who have a negative test result  
For further reading on calculating measures of test accuracy see Loong et al28 
  
Box 3: How patients were involved in the creation of this article 
 
Two patient representatives from the University of Birmingham PPI panel reviewed this article. 
The feedback was that the article was interesting and readable, and the case studies were 
realistic. As a result of the feedback changes were made to the wording of box 5 ‘possible phrases 
to help explain antibody tests to patients’. 
 
Box 4: How this article was made 
 
This article was produced at speed to address an urgent need for evidence. JD has recently led a 
Cochrane systematic review of the diagnostic accuracy of covid-19 antibody tests and this paper is 
based on the evidence from this systematic review, with clinical input from JW and AR.  
 
Box 5: Possible phrases to help explain covid-19 antibody tests to patients 
 
• Antibody tests help us to find out who has had covid-19 in the past 
• They cannot tell us for sure whether you can catch covid-19 in the future 
• If the test is positive then it is likely that you have been infected at some time 
• A negative test result cannot rule out the possibility that you have had covid-19.   
 
Box 6: Uncertainties 
• Most studies on antibody tests are from hospitalised patients – we do not know how well 
these tests work in patients with mild illness who were not hospitalised or asymptomatic 
patients 
• There is a lack of data on test accuracy beyond 35 days – we do not know how well these 
tests will work for infections which occurred >5 weeks ago 
• There is not enough evidence to know whether the presence of antibodies confers lasting 
immunity to protect against future covid-19 infection 
 
Box 7: Education into practice 
• What is the protocol for covid-19 antibody testing in your organisation? 
• How do you explain covid-19 antibody test results to patients? 
• Reflect on a recent case of covid-19 antibody testing – did the test results influence 
clinical management?  
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